Investigational drugs in phase II clinical trials for the treatment of neuroblastoma
Author:
Affiliation:
1. Department of Pediatric Oncology, Istituto G.Gaslini, Genova, Italy
2. Epidemiology and Biostatistics Unit, Istituto G.Gaslini, Genova, Italy
3. Experimental Therapy Unit in Oncology, Istituto G. Gaslini, Genova, Italy
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543784.2017.1380625
Reference91 articles.
1. Improved Response in High-Risk Neuroblastoma With Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing Approach
2. Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Société Française des Cancers de l’Enfant and United Kingdom Children Cancer Study Group–New Agents Group Study
3. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma
4. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
5. Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells;Cancers;2024-05-05
2. Semisynthetic phytochemicals in cancer treatment: a medicinal chemistry perspective;RSC Medicinal Chemistry;2024
3. Future of Clinical Trials and Application of Precision Medicine;Pediatric Oncology;2024
4. Multifunctional Nanoassemblies for Cytotoxic Drug and Therapeutic Enzymes Delivery in Neuroblastoma Therapy;Advanced Materials Interfaces;2022-09-09
5. Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development;Seminars in Cancer Biology;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3